Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05846230 · ClinicalTrials.gov registry record · Phase 2
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
A Phase 2 study of Bronchiectasis, sponsored by Boehringer Ingelheim.
- Active
- Registry status
- Phase 2
- Development phase
- 268
- Enrollment target
- 20
- Study locations
NCT05846230 is a Phase 2 study of Bronchiectasis that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 268 participants, below the 367-participant average among 13 other Bronchiectasis trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05846230, a Phase 2 study of Bronchiectasis, is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 268 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. Participants take a low, medium, or high dose of BI 1291583 as a tablet once a day for up to 1 year. Participants who were taking placebo in the AirleafTM or ClairaflyTM study are put into the BI 1291583 dosage groups randomly, which means by chance. Placebo tablets look like BI1291583 but do not contain any medicine. Participants who were taking BI 1291583 in the AirleafTM or ClairaflyTM study continue to take the same dose. Participants visit the study site 10 times and get 4 phone calls from the site staff. During the visits, the doctors collect information on any health problems of the participants. The doctors also check whether BI 1291583 helps reduce the symptoms of bronchiectasis.
Conditions Studied
Interventions
- DRUG BI 1291583
- DRUG Placebo matching BI 1291583
Study Locations (20)
Texas
- Metroplex Pulmonary & Sleep Center - McKinney
- IMA Clinical Research San Antonio - San Antonio
- University of Texas Health Science Center at Tyler - Tyler
Other
- Universitair Ziekenhuis Gent - Ghent
- UZ Leuven - Leuven
- Medical Center "Zdrave-1" - Kozloduy
California
- Newport Native MD, Inc - Newport Beach
- University of California Davis - Sacramento
Florida
- Malcom Randall VA Medical Center - Gainesville
- University of Florida Health Jacksonville - Jacksonville
New South Wales
- Macquarie University - Macquarie Park
- Westmead Hospital - Westmead
Queensland
- Lung Research Queensland - Chermside
- Mater Research Institute - South Brisbane
Western Australia
- Institute for Respiratory Health - Nedlands
- Trialswest - Spearwood
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2023-09-08 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05846230
The ClinicalTrials.gov registry entry for NCT05846230 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 367-participant average among 13 other Bronchiectasis trials with a reported enrollment target (27% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bronchiectasis appearing as the primary indexed condition, and to 2 interventions - of which BI 1291583 is the first listed.
NCT05846230 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, Other, California.
Frequently Asked Questions
What is clinical trial NCT05846230 about?
NCT05846230 is a clinical study titled "Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine". This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps p...
What is the current status of trial NCT05846230?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 268 participants. The study started on 2023-09-08. Estimated completion is 2027-03-31.
What conditions does trial NCT05846230 study?
This clinical trial studies the following conditions: Bronchiectasis.
What interventions are being tested in trial NCT05846230?
The interventions under investigation include: BI 1291583 (DRUG), Placebo matching BI 1291583 (DRUG).
Who is sponsoring clinical trial NCT05846230?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05846230 being conducted?
This trial has 20 study locations across California, Florida, Kansas, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiectasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
COMPLETED · Phase 2
-
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
COMPLETED · Phase 2
-
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
RECRUITING · Phase 3
-
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
RECRUITING
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
-
Itraconazole Therapy In Bronchiectasis With Airway Mold
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.